Vertex Pharmaceuticals (VRTX) - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92532F1003

Vertex Pharmaceuticals Incorporated is a biotechnology company that focuses on creating and bringing to market therapies for individuals living with cystic fibrosis (CF). They offer a range of treatments such as TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to address the specific needs of CF patients of varying ages and genetic mutations.

With a strong pipeline of innovative medications, Vertex Pharmaceuticals is advancing treatments like VX-522 and VX-548 for CF, Exa-cel for sickle cell disease and beta thalassemia, and inaxaplin for APOL1-mediated focal segmental glomerulosclerosis. The company is also exploring therapies for Type 1 Diabetes, cancer, and additional conditions to meet diverse medical needs.

Furthermore, Vertex Pharmaceuticals collaborates with leading institutions and biotech companies like CRISPR Therapeutics AG, Moderna, Inc., and Arbor Biotechnologies, Inc. to drive research and development efforts. They strive to expand their reach and impact on various diseases through strategic partnerships and innovative approaches.

Vertex Pharmaceuticals Incorporated not only develops groundbreaking treatments but also ensures the availability of their products through partnerships with specialty pharmacies and distributors. Based in Boston, Massachusetts, the company continues to push boundaries in biotechnology and make a positive difference in patients' lives.

For more information, you can visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Vertex Pharmaceuticals (VRTX) - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Vertex Pharmaceuticals (VRTX) - Stock & Dividends

VRTX Stock Overview

Market Cap in USD 104,359m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 1991-07-24

VRTX Stock Ratings

Growth 5y 7.41
Fundamental 6.10
Dividend -
Rel. Performance vs Sector 1.43
Analysts 3.78/5
Fair Price Momentum 376.09 USD
Fair Price DCF 355.00 USD

VRTX Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

VRTX Growth Ratios

Growth 12m 19.54%
Growth Correlation 12m 65%
Growth Correlation 3m -67%
CAGR 5y 18.43%
Sharpe Ratio 12m 0.60
Alpha vs SP500 12m 2.95
Beta vs SP500 5y weekly 0.64
ValueRay RSI 7.59
Volatility GJR Garch 1y 26.03%
Price / SMA 50 -5%
Price / SMA 200 3.04%
Current Volume 948.8k
Average Volume 20d 909.5k

External Links for VRTX Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of VRTX stocks?
As of April 19, 2024, the stock is trading at USD 393.48 with a total of 948,806 shares traded.
Over the past week, the price has changed by -1.69%, over one month by -4.35%, over three months by -9.12% and over the past year by +21.01%.
What is the forecast for VRTX stock price target?
According to ValueRays Forecast Model, VRTX Vertex Pharmaceuticals will be worth about 415.8 in April 2025. The stock is currently trading at 393.48. This means that the stock has a potential upside of +5.66%.
Issuer Forecast Upside
Wallstreet Target Price 465 18.2%
Analysts Target Price 388.7 -1.22%
ValueRay Target Price 415.8 5.66%

Vertex Pharmaceuticals Inc: A Comprehensive Overview

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), founded in 1989, has grown into a leading global biotechnology firm committed to creating transformative medicines for people with serious diseases.

The Heart of Vertex: Cystic Fibrosis

The core focus of Vertex's research and development efforts has been on Cystic Fibrosis (CF), a critical genetic disorder that affects the lungs and digestive system. Pioneering in this field, Vertex has successfully brought to market several treatments that address the underlying cause of CF rather than its symptoms, significantly improving patients' quality of life.

Expanding the Portfolio: Beyond Cystic Fibrosis

While maintaining cystic fibrosis at its core, Vertex has not rested on its laurels. The company has gradually diversified its research portfolio to include other serious diseases. This includes research into pain, infectious diseases, and cancer, amongst others. These endeavors underscore Vertex's commitment to broadening its impact on healthcare by exploring new therapeutic areas.

Current Market Status

As of 2023, Vertex Pharmaceuticals remains a strong player in the biotech industry, thanks to its robust portfolio of CF treatments and burgeoning research into other therapeutic areas. The company has consistently demonstrated financial growth and resilience, partly due to its strategic investments in research and development. Vertex's presence in the market underscores its dedication not only to shareholder value but also to a future where more patients can benefit from innovative therapies.

For more details on the innovative work and the latest news from Vertex Pharmaceuticals, visit their official website here.